Pro-inflammatory cytokine and mediator (PIC)

Pro-inflammatory cytokine and mediator represent a diverse group of signaling molecules, including proteins such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), as well as lipid-derived factors like prostaglandins, that initiate and amplify the inflammatory response (Dinarello, 2000). These molecules are primarily produced by activated macrophages, T-cells, and endothelial cells in response to pathogens or tissue damage to coordinate immune cell recruitment and activation (Nature Reviews Immunology, 2002). While essential for acute host defense and wound healing, their chronic overproduction is a central driver of systemic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis (StatPearls, 2023). In clinical practice, these mediators are targeted by a wide array of therapeutics, ranging from monoclonal antibodies that sequester specific cytokines to small molecules that inhibit their synthesis or downstream signaling (PubMed, 2021). However, because these mediators play fundamental roles in immune surveillance, their therapeutic inhibition carries significant risks, most notably an increased susceptibility to serious bacterial, viral, and fungal infections (NIH, 2022). Monitoring biomarkers such as C-reactive protein and specific cytokine levels is often necessary to assess disease activity and treatment response in patients receiving these therapies.

Other names

Inflammatory cytokinePro-inflammatory factorInflammatory mediatorAlarmins

The primary mechanisms of action for drugs targeting these mediators include the direct neutralization of circulating ligands (e.g., anti-TNF antibodies), competitive inhibition of cytokine receptors (e.g., IL-1 receptor antagonists), and the blockade of intracellular signaling pathways such as the Janus kinase (JAK) pathway (StatPearls, 2023; PubMed, 2021).